M
Michael J. Sateia
Researcher at Dartmouth College
Publications - 49
Citations - 8314
Michael J. Sateia is an academic researcher from Dartmouth College. The author has contributed to research in topics: Sleep medicine & Sleep disorder. The author has an hindex of 20, co-authored 49 publications receiving 6506 citations. Previous affiliations of Michael J. Sateia include Dartmouth–Hitchcock Medical Center.
Papers
More filters
Journal ArticleDOI
International classification of sleep disorders-third edition: highlights and modifications.
TL;DR: Significant modifications have been made to the nosology of insomnia, narcolepsy, and parasomnias in the recently released third edition of the International Classification of Sleep Disorders.
Journal ArticleDOI
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
TL;DR: This clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist.
Journal Article
Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine.
Nancy A. Collop,W. McDowell Anderson,Brian Boehlecke,Rochelle Goldberg,Daniel J. Gottlieb,David W. Hudgel,Michael J. Sateia,Richard Schwab,James A. Haley +8 more
TL;DR: PM testing be performed under the auspices of an AASM-accredited comprehensive sleep medicine program with written policies and procedures and must allow for display of raw data with the capability of manual scoring or editing of automated scoring by a qualified sleep technician/technologist.
Journal ArticleDOI
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline
TL;DR: This guideline is designed to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated, and includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication.